{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:43:17Z","timestamp":1790008997671,"version":"4.0.1"},"reference-count":29,"publisher":"BMJ","issue":"19","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2016,4,29]]},"published-print":{"date-parts":[[2016,10,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To analyse time to cardiovascular events and mortality in patients with type 2 diabetes (T2D) who received treatment intensification with insulin or a glucagon-like peptide-1 (GLP-1ar) analogue following dual therapy failure with metformin (MET) and sulphonylurea (SU).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study was conducted in 2003 patients who were newly treated with a GLP-1ar or insulin following dual therapy (MET+SU) failure between 2006 and 2014. Data were sourced from The Health Improvement Network database. Risks of major adverse cardiovascular events (MACE) (non-fatal myocardial infarction, non-fatal stroke and all-cause mortality) were compared between MET+SU+insulin (N=1584) versus MET+SU+GLP-1ar (N=419). Follow-up was for 5\u2005years (6614 person-years). Propensity score matching analysis and Cox proportional hazard models were employed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Mean age was 52.8\u00b114.1\u2005years. Overall, the number of MACE was 231 vs 11 for patients who added insulin versus GLP-1ar, respectively (44.5 vs 7.7 per 1000-person-years adjusted HR (aHR): 0.27; 95% CI 0.14 to 0.53; p&lt;0.0001). Insulin was associated with significant increase in weight compared with GLP-1ar (1.78 vs \u22123.93\u2005kg; p&lt;0.0001) but haemoglobin A1c reduction was similar between both treatment groups (\u22121.29 vs \u22120.98; p=0.156). In a subgroup analysis of obese patients (body mass index &gt;30\u2005kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) there were 84 vs 11 composite outcomes (38.6 vs 8.1 per 1000 person-years; aHR: 0.31; 95% CI 0.16 to 0.61; p=0.001) in the insulin and GLP-1ar groups, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this cohort of obese people with T2DM, intensification of dual oral therapy by adding GLP-1ar analogue is associated with a lower MACE outcome in routine clinical practice, compared with adding insulin therapy as the third glucose-lowering agent.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/heartjnl-2015-309164","type":"journal-article","created":{"date-parts":[[2016,5,23]],"date-time":"2016-05-23T23:38:30Z","timestamp":1464046710000},"page":"1581-1587","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":32,"title":["Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes"],"prefix":"10.1136","volume":"102","author":[{"given":"Uchenna","family":"Anyanwagu","sequence":"first","affiliation":[{"name":"Division of Medical Sciences & Graduate Entry Medicine, School of Medicine, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jil","family":"Mamza","sequence":"additional","affiliation":[{"name":"Division of Medical Sciences & Graduate Entry Medicine, School of Medicine, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajnikant","family":"Mehta","sequence":"additional","affiliation":[{"name":"Research Design Services (East Midlands), School of Medicine, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Donnelly","sequence":"additional","affiliation":[{"name":"Division of Medical Sciences & Graduate Entry Medicine, School of Medicine, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iskandar","family":"Idris","sequence":"additional","affiliation":[{"name":"Division of Medical Sciences & Graduate Entry Medicine, School of Medicine, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2016,5,23]]},"reference":[{"key":"2025101712161821000_102.19.1581.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806470"},{"key":"2025101712161821000_102.19.1581.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60697-8"},{"key":"2025101712161821000_102.19.1581.3","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0140-6736(09)61457-4","article-title":"10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study","volume":"374","author":"Diabetes Prevention Program Research Group","year":"2009","journal-title":"The Lancet"},{"key":"2025101712161821000_102.19.1581.4","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.schbul.a033504"},{"key":"2025101712161821000_102.19.1581.5","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2441"},{"key":"2025101712161821000_102.19.1581.6","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.2007.S5"},{"key":"2025101712161821000_102.19.1581.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa072761"},{"key":"2025101712161821000_102.19.1581.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60794-7"},{"key":"2025101712161821000_102.19.1581.9","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-3042"},{"key":"2025101712161821000_102.19.1581.10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.4312"},{"key":"2025101712161821000_102.19.1581.11","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-1318"},{"key":"2025101712161821000_102.19.1581.12","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-1393"},{"key":"2025101712161821000_102.19.1581.13","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/215764"},{"key":"2025101712161821000_102.19.1581.14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5922.2010.00256.x"},{"key":"2025101712161821000_102.19.1581.15","first-page":"251","article-title":"Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates","volume":"19","author":"Blak","year":"2011","journal-title":"Inform Prim Care"},{"key":"2025101712161821000_102.19.1581.16","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1335"},{"key":"2025101712161821000_102.19.1581.17","doi-asserted-by":"crossref","first-page":"e000021","DOI":"10.1136\/bmjdrc-2014-000021","article-title":"Obesity independently predicts responders to biphasic insulin 50\/50 (Humalog Mix50 and Insuman Comb 50) following conversion from other insulin regimens: a retrospective cohort study","volume":"2","author":"Mamza","year":"2014","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2025101712161821000_102.19.1581.18","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-015-0110-6"},{"key":"2025101712161821000_102.19.1581.19","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-014-0162-3"},{"key":"2025101712161821000_102.19.1581.20","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-014-0483-3"},{"key":"2025101712161821000_102.19.1581.21","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2009.48"},{"key":"2025101712161821000_102.19.1581.22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f4533"},{"key":"2025101712161821000_102.19.1581.23","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.7.1142"},{"key":"2025101712161821000_102.19.1581.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.11.006"},{"key":"2025101712161821000_102.19.1581.25","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-1797"},{"key":"2025101712161821000_102.19.1581.26","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12406"},{"key":"2025101712161821000_102.19.1581.27","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12003"},{"key":"2025101712161821000_102.19.1581.28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2008.00964.x"},{"key":"2025101712161821000_102.19.1581.29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2006.00686.x"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2015-309164","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T19:16:26Z","timestamp":1760728586000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2015-309164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,23]]},"references-count":29,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2016,9,13]]},"published-print":{"date-parts":[[2016,10,1]]}},"alternative-id":["10.1136\/heartjnl-2015-309164"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2015-309164","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,23]]}}}